FGFR1 Fusion Detection in Osteosarcoma Targeted Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteosarcoma, including precision oncology and immunotherapy, are not effective, and there is a lack of biologic subtypes associated with treatment response and resistance, limiting the development of targeted therapy options.
Innovation Solution
Detecting FGFR1-MTSS1 or TACC1-FGFR1 gene fusions in osteosarcoma patients and administering an effective amount of an anti-cancer agent, such as an FGFR1 inhibitor, tyrosine kinase inhibitor, or pan-kinase inhibitor.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments including precision oncology and immunotherapy are used for osteosarcoma, then general cancer treatment approaches are applied, but treatment effectiveness is poor and survival rates remain low
Solution Approach 1:
The patent applies local quality by identifying specific gene fusion alterations (FGFR1-MTSS1 and TACC1-FGFR1) within the broader osteosarcoma context. Rather than treating all osteosarcoma patients uniformly, the invention focuses on a specific molecular subgroup defined by these gene fusions, providing tailored targeted therapy with FGFR1 inhibitors to this particular population, thereby improving treatment effectiveness for responsive patients
Solution Approach 2:
The patent segments osteosarcoma patients into distinct biologic subtypes based on gene fusion status. By dividing the heterogeneous osteosarcoma population into those with FGFR1-MTSS1/TACC1-FGFR1 fusions and those without, the invention enables stratified treatment approaches, allowing precision oncology to be implemented through molecular classification
2Adaptability or versatility
If genome sequencing and molecular classification are performed to identify biologic subtypes, then treatment personalization is enabled, but diagnostic complexity and cost increase
Solution Approach 1:
The patent extracts the critical diagnostic information needed for subtype identification by focusing specifically on detecting FGFR1-MTSS1 and TACC1-FGFR1 gene fusions. Rather than requiring comprehensive genome sequencing, the invention isolates and targets these specific fusion events, simplifying the diagnostic workflow while enabling biologic subtype classification
Solution Approach 2:
The patent introduces gene fusion detection as an intermediary step between standard diagnostics and targeted therapy selection. By using molecular classification through fusion detection as a mediator, the system bridges the gap between conventional treatment approaches and precision oncology, enabling treatment personalization without requiring full genomic analysis
Data Source
AI summary
Provided herein are methods related to treating or delaying progression of osteosarcoma in an individual. In some embodiments, the methods comprise detecting an FGFR1-MTSS1 or TACC1-FGFR1 gene fusion in one or more samples from an individual having a cancer; and administering to the individual an effective amount of a treatment that comprises an anti-cancer agent.